Ratings AdaptHealth Corp.

Equities

AHCO

US00653Q1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
9.78 ^USD	-0.31%		+3.71%	+34.16%

Apr. 17	AdaptHealth Names Suzanne Foster as CEO	MT
Apr. 17	AdaptHealth Names Suzanne Foster CEO	DJ

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The company's share price in relation to its net book value makes it look relatively cheap.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company has insufficient levels of profitability.
The group shows a rather high level of debt in proportion to its EBITDA.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
ADAPTHEALTH CORP.	+34.16%	1.3B	D+
ABBOTT LABORATORIES	-2.89%	185B	C+
MEDTRONIC PLC	-2.43%	107B	C
BECTON, DICKINSON AND COMPANY	-4.10%	67.55B	A
DEXCOM, INC.	+11.10%	54.6B	B-
CENCORA, INC.	+15.86%	47.42B	B-
HOYA CORPORATION	+3.86%	42.24B	B+
WEST PHARMACEUTICAL SERVICES, INC.	+9.55%	28.24B	A-
METTLER-TOLEDO INTERNATIONAL, INC.	+1.85%	26.42B	B
TERUMO CORPORATION	+12.40%	25.66B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes